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the biases associated with the woodwork effect were statis-
tically significant (fluoxetine P  0.0055, paroxetine P 
0.0041, and sertraline P  0.3261). None of antidepres-
sant selection biases were significant. No statistical signif-
icance differences were found in total health care costs
for patients initiating therapies with these three SSRIs as
compared with TCAs. However, in models with a single
 to adjust only for treatment selection bias, the fluoxet-
ine group had significant drug selection bias (P 
0.0418) and significant high total health care cost as
compared with TCAs (P  0.0076). CONCLUSION:
Double- method better resolved the selection biases in
antidepressant therapy in an evaluation of the impact of
alternative therapies on post-treatment costs following a
formulary change than the Heckman-Lee method.
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Receiver operating characteristic (ROC) analysis is often
used to assess the screening accuracy of continuous mea-
sures. Hanley and McNeil (Radiology 1983;148:839–
843) developed a method for comparing ROC curves
that is widely used in the literature. DeLong et al. (Bio-
metrics 1988;44:837–845) subsequently developed an
improved method; however, it has not become popular
due to its perceived complexity. OBJECTIVE: This re-
search compared the method of DeLong et al. to that of
Hanley and McNeil. METHODS: The data were drawn
from a sample of over 1,215 primary care patients partic-
ipating in the Longitudinal Investigation of Depression
Outcomes (LIDO) study. Three continuous measures (i.e.,
CES-D, MHI-5, and MCS-12) were compared in terms of
their ability to detect diagnosis of major depression based
on the CIDI. Values for area under the ROC curve (AUC)
were computed for the three measures and compared sta-
tistically using the DeLong et al. and Hanley and McNeil
methods. RESULTS: The two methods yielded entirely
different statistical conclusions. Using the DeLong et al
method, z statistics for difference between AUC values
were 15–22% larger. The DeLong et al method yielded
confidence intervals that were 17–25% narrower than
those derived using the method of Hanley and McNeil.
The statistical efficiency of the Hanley and McNeil
method relative to that of DeLong et al ranged from 64–
73%. CONCLUSIONS: The DeLong et al method is
more elegant and precise than that developed by Hanley
and McNeil. The results of this investigation indicate that
the former would require fewer patients than the latter to
achieve a fixed level of statistical power.
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For many people, postoperative pain is suboptimally con-
trolled, however, limited information is available about
pain from the patient’s perspective. OBJECTIVES: A
purpose of this pilot study was to describe patient’s post-
operative pain after abdominal or orthopedic surgery.
METHODS: Seventeen persons who underwent total ab-
dominal hysterectomy (TAH), or total hip or knee re-
placement (THR, TKR) between August and November
1999 completed a modified version of the American Pain
Society (APS) Quality Improvement questionnaire within
24 hours before leaving the hospital. Pain was rated on a
0 (no pain) – 10 (worst pain possible) analog scale. RE-
SULTS: Mean age was 43.7 years for TAH (n  7), 55.0
years for THR (n  4), and 61.8 years for TKR patients
(n  6). Mean length of stay (days) was 3.6 overall, 3.2
for TAH, 3.8 for THR, and 4.2 for TKR. All patients had
pain within 24 hours before leaving the hospital. At the
time patients completed the survey, mean pain levels
were 4.1, 3.2, and 2.2 for persons after TAH, THR, and
TKR, respectively. Mean worst pain was 9.1, 7.8, and
8.0 for TAH, THR, and TKR patients, respectively. Pain
was most severe on the first or second day after surgery
for 86.7%, 75.0%, and 100% of TAH, THR, and TKR
patients, respectively. CONCLUSIONS: Postoperative
pain was most severe on the first and second days after
surgery for most patients. Postoperative pain levels at dis-
charge suggest that patients will require additional anal-
gesia at home.
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In Portugal (population 10 million), 12% of the adult
population is obese (BMI 30) and almost 50% are
overweight (BMI 25). These persons have an increased
risk of morbidity and premature death due to various dis-
eases (e.g. type II diabetes, hypertension, coronary heart
disease and some forms of cancer). OBJECTIVES: To
calculate the direct economic cost of illness associated
with obesity in Portugal. METHODS: A prevalence-
based COI approach is adopted. Data are drawn from
the National Health Survey, the hospital information sys-
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tem (based on DRG’s) and IMS-Portugal. The main cost
categories included are hospitalization, ambulatory care
and pharmaceuticals. Obesity population attributable
fraction (PAF) are calculated for ten co-morbidities. Rel-
ative risks are drawn from large-scale prospective inter-
national studies and prevalence data from national
sources. RESULTS: The direct cost of obesity in Portugal
in 1996 was estimated as PTE 46.2 billion. This corre-
sponds to 3.5% of annual health care expenditure, a share
larger than in 5 of the six countries where comparable
studies have been carried out (the exception being the U.S.).
The largest cost component is expenditure on pharmaceuti-
cals (43%), followed by hospitalization (29%) and ambu-
latory care (28%). Drug costs are attributable largely to cir-
culatory system pathologies, particularly hypertensive
diseases. Annually more than 35,000 inpatient episodes
are attributable to obesity and the problem is responsible
for over 2 million doctor visits. CONCLUSIONS: A con-
siderable proportion of Portuguese health spending is
used in treating obesity co-morbidities. Preventive and
therapeutic strategies that reduce obesity prevalence can
potentially bring about significant cost-savings. More re-
search is needed on the benefits and cost-effectiveness of
strategies aimed at reducing obesity.
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Colorectal cancer is the third most common cancer in
Canada with approximately 16,500 new cases in 1999.
Currently, 5-fluorouracil (5-FU) plus leucovorin is stan-
dard chemotherapeutic treatment. Raltitrexed, is a new
class of cytotoxic drug. OBJECTIVE: To measure from a
Canadian Ministry of Health perspective the economic
value of raltitrexed 3 mg/m2 once every three weeks and
425 mg/m2 5-FU plus 20 mg/m2 leucovorin for 5 days re-
peated every 28 days. Results of the study, a large North
American trial, are reported elsewhere. In this abstract,
results of Canadian patients are reported; specifically,
cost per quality adjusted survival. METHODS: Quality
adjustments were conducted by rewarding survival time
without toxicities and disease progression while penaliz-
ing time with toxicities or disease progression. Health-
care costs by type of resource and economic perspective
were collected from five centers that participated in the
clinical trial in Quebec and Ontario. RESULTS: 103 pa-
tients were eligible for analyses, 50 in the 5-FULV
group and 53 in the raltitrexed group. Without adjust-
ment for quality versus quantity of survival, the median
time to death from Kaplan Meier estimates were equiva-
lent, 496 and 493 days, respectively. Both time to pro-
gression and time with toxicities favored patients treated
with raltitrexed. Thus, quality adjusted survival favored
patients treated with raltitrexed, 269 versus 370 days at
the median. Direct drug cost favored 5-FULV, $130
versus $1005 for an average cost difference of $875;
nonetheless, the incremental cost per QALY for raltitrexed
was $3159 (95%CI: $1626–$4692). When other direct
medical costs were included raltitrexed became cost sav-
ing. CONCLUSIONS: Raltitrexed offers a more conve-
nient treatment regimen than 5-FU plus leucovorin and is
as effective while causing less toxicity.
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ACEIs reduce CHF mortality and hospitalization. How-
ever, commonly prescribed doses are often much lower
than target doses used in randomized clinical trials (RCTs)
and recommended by evidence-based practice guidelines.
In ATLAS, a RCT of high (32.5–35 mg) versus low (2.5–
5 mg) dose lisinopril in 3164 class II–IV CHF patients
with left ventricular ejection fraction 30% in 19 coun-
tries over 3 years, mortality risk was reduced 8% (P 
0.128); mortality and hospitalization risk was reduced
12% (P  0.002). OBJECTIVES: To assess the cost-ef-
fectiveness of high versus low dose lisinopril in the 1198
(high dose 592, low dose 606) US ATLAS patients.
METHODS: Hospital costs were estimated using man-
aged care diagnosis-related group reimbursement rates;
drug costs using average wholesale prices. Costs were dis-
counted at 3% per year. Statistical analyses were com-
puted using Wilcoxon rank-sum tests for hospitalizations
and T-test for log-transformed costs. RESULTS: High
dose lisinopril reduced CHF and total hospitalizations
(both P  0.050). In the US, hospitalizations per patient
were reduced 0.19 and hospitalization costs per patient
was reduced $950. Drug costs per patient increased
($1224 versus $688; P  0.001). Total costs per patient
decreased ($19,254 versus $19,709; P  0.038), result-
ing from decreased CHF hospitalizations. Cost savings
increased further when worldwide ATLAS patients and
hospitalizations were included. CONCLUSIONS: The in-
creased costs of high versus low dose lisinopril are more
than offset by cost savings from decreased CHF hospital-
izations. High dose lisinopril improves clinical outcomes
at reduced cost.
